Democratic Republic of the CongoTuberculosis profile
Population  2014 75 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 52 (38–68) 69 (50–90)
Mortality (HIV+TB only) 6.3 (5–7.7) 8.4 (6.7–10)
Prevalence  (includes HIV+TB) 400 (210–640) 532 (282–859)
Incidence  (includes HIV+TB) 240 (220–270) 325 (295–356)
Incidence (HIV+TB only) 34 (27–42) 45 (36–56)
         
Case detection, all forms (%) 48 (43–52)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
2 000 (270–3 700) 790 (450–1 100)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 75 631   4 298
Pulmonary, clinically diagnosed 13 494   1 892
Extrapulmonary 19 566   914
       
Total new and relapse 115 795    
Previously treated, excluding relapses 1 099    
Total cases notified 116 894    
Among 75 631 new cases:
3 438 (5%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 545 (<1%) 6 135 (75%) 6 817
Laboratory-confirmed RR-/MDR-TB cases     442
Patients started on MDR-TB treatment ***     436
TB/HIV 2014 Number (%)
TB patients with known HIV status 53 285 (46)
HIV-positive TB patients 7 206 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 671 (79)
HIV-positive TB patients on antiretroviral therapy (ART) 4 799 (67)
HIV-positive people screened for TB 33 743  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (87) 112 439
Previously treated cases registered in 2013 (66) 1 164
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (64) 134
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 39
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 55
% Funded domestically 5%
% Funded internationally 50%
% Unfunded 44%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-25 Data: www.who.int/tb/data